Free Trial
NYSE:BIO

Bio-Rad Laboratories (BIO) Stock Price, News & Analysis

$304.15
+8.63 (+2.92%)
(As of 07/12/2024 ET)
Today's Range
$297.54
$304.44
50-Day Range
$263.67
$304.40
52-Week Range
$261.59
$431.79
Volume
301,850 shs
Average Volume
300,066 shs
Market Capitalization
$8.67 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$436.67

Bio-Rad Laboratories MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
43.6% Upside
$436.67 Price Target
Short Interest
Bearish
6.50% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.54
Upright™ Environmental Score
News Sentiment
0.66mentions of Bio-Rad Laboratories in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$104,025 Sold Last Quarter
Proj. Earnings Growth
8.80%
From $10.80 to $11.75 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.35 out of 5 stars

Medical Sector

122nd out of 917 stocks

Analytical Instruments Industry

5th out of 27 stocks

BIO stock logo

About Bio-Rad Laboratories Stock (NYSE:BIO)

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

BIO Stock Price History

BIO Stock News Headlines

I’ve seen this situation a handful of times in my life
The stock is now trading for just $10 a share. Why is this company being ignored by Wall Street, and what kind of gains could shareholders soon be looking at?
Precision BioSciences earnings: here's what Wall Street expects
Q1 2024 Bio Rad Laboratories Inc Earnings Call
I’ve seen this situation a handful of times in my life
The stock is now trading for just $10 a share. Why is this company being ignored by Wall Street, and what kind of gains could shareholders soon be looking at?
See More Headlines
Receive BIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Rad Laboratories and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/07/2024
Today
7/13/2024
Next Earnings (Estimated)
8/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
CUSIP
09057220
Employees
8,030
Year Founded
1952

Price Target and Rating

Average Stock Price Target
$436.67
High Stock Price Target
$550.00
Low Stock Price Target
$315.00
Potential Upside/Downside
+43.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$-637,320,000.00
Pretax Margin
-17.04%

Debt

Sales & Book Value

Annual Sales
$2.67 billion
Cash Flow
$12.47 per share
Book Value
$306.51 per share

Miscellaneous

Free Float
23,659,000
Market Cap
$8.68 billion
Optionable
Optionable
Beta
0.93

Social Links

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Norman D. Schwartz (Age 74)
    Chairman, CEO & President
    Comp: $1.25M
  • Dr. Andrew J. Last Ph.D. (Age 64)
    Executive VP & COO
    Comp: $682.29k
  • Mr. Roop K. Lakkaraju (Age 53)
    Executive VP & CFO
  • Ms. Tania DeVilliers (Age 50)
    Senior Director, Corporate Controller & Interim Principal Accounting Officer
  • Mr. Yong Chung
    Vice President of Investor Relations
  • Matthew Werner
    Senior Vice President and Chief Compliance & Privacy Officer
  • Courtney C. Enloe
    Executive VP, General Counsel & Secretary
  • Ms. Colleen Corey (Age 62)
    Executive Vice President of Global Human Resources
  • Mr. Michael CrowleyMr. Michael Crowley (Age 62)
    Executive Vice President of Global Commercial Operations
    Comp: $974.94k
  • Lee Boyd
    Senior Vice President of Global Commercial Operations - Asia Pacific

BIO Stock Analysis - Frequently Asked Questions

How have BIO shares performed this year?

Bio-Rad Laboratories' stock was trading at $322.89 at the start of the year. Since then, BIO stock has decreased by 5.8% and is now trading at $304.15.
View the best growth stocks for 2024 here
.

How were Bio-Rad Laboratories' earnings last quarter?

Bio-Rad Laboratories, Inc. (NYSE:BIO) released its quarterly earnings data on Tuesday, May, 7th. The medical research company reported $2.29 EPS for the quarter, topping the consensus estimate of $2.04 by $0.25. The firm's revenue for the quarter was down 9.8% compared to the same quarter last year.
Read the conference call transcript
.

What is Norman Schwartz's approval rating as Bio-Rad Laboratories' CEO?

325 employees have rated Bio-Rad Laboratories Chief Executive Officer Norman Schwartz on Glassdoor.com. Norman Schwartz has an approval rating of 84% among the company's employees.

Does Bio-Rad Laboratories have any subsidiaries?

The following companies are subsidiaries of Bio-Rad Laboratories: Dropworks Inc., Celsee, Raindance Technologies Limited, GnuBIO Inc., Bio-Rad AbD Serotec GmbH, Propel Labs - Cell Sorting System Division, QuantaLife, and more.

Who are Bio-Rad Laboratories' major shareholders?

Bio-Rad Laboratories' top institutional investors include Polianta Ltd (0.01%), Harbor Capital Advisors Inc. (0.01%), DNB Asset Management AS (0.01%) and Park Avenue Securities LLC (0.01%). Insiders that own company stock include Michael Crowley, Timothy S Ernst, Dara Wright, Ilan Daskal, Ajit Ramalingam and Annette Tumolo.
View institutional ownership trends
.

How do I buy shares of Bio-Rad Laboratories?

Shares of BIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Bio-Rad Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bio-Rad Laboratories investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AbbVie (ABBV), NVIDIA (NVDA), Broadcom (AVGO) and Johnson & Johnson (JNJ).

This page (NYSE:BIO) was last updated on 7/13/2024 by MarketBeat.com Staff

From Our Partners